Endocrinology

Compared to nonusers, patients with type 2 diabetes and acute kidney disease administered SGLT-2is had a significantly lower risk of mortality, major adverse kidney events, and major adverse cardiovascular events.

Hosts discuss a recent study on baricitinib in type 1 diabetes, how these results compare to other data in this arena, and what all of these studies mean for future of type 1 diabetes management.

To celebrate the end of 2023, hosts recap the top 10 episodes of the past year and offer perspective on how the news discussed in these episodes has shaped the future of diabetes management.

Hosts discuss what they consider the most significant or relevant updates in the ADA's Standards of Care—2024, with a focus on new recommendations for glycemic management, bone health, immunizations, and weight management.

This endocrine case report from Brady Pregerson, MD, features a woman in her early 50s with a history of type 2 diabetes and hypothyroidism presenting with 5 days of epigastric pain. Can you determine the correct diagnosis?

A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.

Mendelian randomization analyses demonstrated a causal relationship between hypothyroidism and diabetes, along with its related microvascular complications.

SGLT2 inhibitors show a reduced risk of retinopathy compared with DPP-4 inhibitors, pioglitazone, and sulfonylureas among patients with type 2 diabetes.

Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

Maternal height is linked to specific adverse pregnancy events in women with gestational diabetes mellitus, according to a new study. The investigators found shorter women had higher rates of low birth rate and primary c-sections, but taller women had higher rates of abnormal neonatal ponderal index, postpartum hemorrhage, and macrosomia.

Addressing a lack of quantitative data on AID, this study used validated measures in a real-world setting to corroborate the psychosocial benefits seen in prior qualitative research.

A review and meta-analysis of 29 studies found systolic blood pressure significantly decreased in the semaglutide group compared with placebo or other active controls.

New data highlights the need for improved communication and understanding of barriers is evident for the effective management of type 2 diabetes.

More than half of patients who received a pancreas transplant alone experienced >50% decline in eGFR, had eGFR < 30 mL/min/1.73 m2, and/or received a kidney transplant 10 years after their initial pancreas transplant.

Tight glycemic target treatment compares similarly to less-tight glycemic target treatment in terms of how it affects the mental health status of women with gestational diabetes mellitus.

Despite the known association between infectious disease and type 1 diabetes, results showed no impact on risk of latent autoimmune diabetes in adults.

Among adults in middle- to high-income nations, awareness of diabetes as a cardiovascular risk factor remains a persistent issue.

In the Dapa-ON trial, the careful selection of people with T1D and the implementation of strategies to reduce the risk of DKA were associated with dapagliflozin's appropriate safety profile.

This episode features a discussion on a pair of AID system integrations with the Dexcom G7 CGM system as well as important updates in the diabetes technology portion from the ADA's Standards of Care—2024.

Global incidence of T1D among children and adolescents <20 years old is substantial, but these rates exhibited significant variability by country, region, and age group.

Patients with T1D diabetic retinopathy showed a longer duration of diabetes and increased age, compared to those without retinopathy.

Following years of concerns about the stigmatization and inaccurate etiology of nonalcoholic fatty liver disease nomenclature, 2023 finally saw revised terminology for liver disease with the implementation of metabolic dysfunction-associated steatotic liver disease.

Results from the MOMPOD RCT indicate metformin added to insulin did not reduce the frequency of a composite adverse neonatal outcome in pregnant adults with diabetes.

Multinational data support the safety of drug classes like GLP-1 agonists during early relative to infant risk of major congenital malformations.